REG - AstraZeneca PLC - Chair succession planning update and Annual Report

AstraZenecaAnnouncement

22/02/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220222:nRSV3462Ca&default-theme=true

RNS Number : 3462C  AstraZeneca PLC  22 February 2022

 

22 February 2022 11:00 GMT

 

Update on Succession Planning for Chair of the Board and Publication of Annual
Financial Report

 

AstraZeneca PLC (the Company) announced today that Leif Johansson,
Non-Executive Chair of the Board, intends to retire from the Board at the
conclusion of the Company's Annual General Meeting (AGM) in 2023.

 

Mr Johansson was first elected to the Board in April 2012 and reached nine
years' tenure as a Director in April 2021. Last year, the Board asked him to
seek re-election at the 2021 AGM to lead the Board's oversight of completion
of the acquisition of Alexion. Again this year, the Board believes it would be
in the best interests of shareholders for Mr Johansson to seek re-election at
the AGM in April 2022 and continue to serve as Chair for one further year, to
facilitate succession planning and the transition to a new Chair.

 

The search for a new Chair is proceeding well, led by Philip Broadley, senior
independent Non-Executive Director.

 

The Company also announced today the publication of its Annual Report and Form
20-F Information 2021 (the Annual Report).

 

A copy of the Annual Report has been submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

The Annual Report is also available on the Company's website at:
www.astrazeneca.com/annualreport2021
(https://www.astrazeneca.com/annualreport2021) .

 

The Annual Report will be dispatched to shareholders in due course.

 

The Company's AGM will take place on 29 April 2022. The Notice of AGM and
Shareholders' Circular will be published and distributed to shareholders in
due course.

 

 

EXPLANATORY NOTE

For the purposes of complying with the Disclosure and Transparency Rules (DTR)
and the requirements imposed on issuers through the DTRs, the Annual Report,
as submitted to the National Storage Mechanism, contains the following
regulated information in unedited form:

 

-    The principal risks and uncertainties facing the Company;

-    The Directors' responsibility statement made in respect of the
Financial Statements and Directors' Report contained in the Annual Report; and

-     A statement regarding related party transactions.

 

A copy of the Annual Report is available on the Company's website and has also
been submitted to the National Storage Mechanism, where it will shortly be
available for inspection.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in Oncology,
Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge, UK,
AstraZeneca operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please visit astrazeneca.com
(http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca
(https://twitter.com/AstraZeneca) .

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSKFLFLLLLXBBB